Drugs / GSK2586881
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT03000686 | May 2017 → Jan 2019 | — | GlaxoSmithKline | Terminated | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT03177603 | Feb 2018 → May 2019 | pulmonary arterial hypertension | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01597635 | Sep 2012 → Oct 2014 | acute lung injury | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT05065645 Comparator | Oct 2021 → May 2022 | COVID-19 | Apeiron Biologics | Completed | No outcome recorded |
| Phase 1 | NCT00886353 Comparator | Apr → Nov 2009 | cardiovascular disorder, kidney disorder, lung disorder | Apeiron Biologics | Completed | No outcome recorded |
| Phase 2 | NCT04335136 Comparator | Apr → Dec 2020 | COVID-19 | Apeiron Biologics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-03 | invIOs GmbH | Results Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01 invios.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-03 | invIOs GmbH | Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01 invios.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2586881 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03000686 ↗ |
| Known as | Alunacedase alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297887 ↗ |
| Known as | APN01 | “APN01 is a soluble recombinant human angiotensin-converting enzyme 2 (rhACE2), a key player in the renin-aldosterone-angiotensin system (RAAS).” PMID 38375429 ↗ Feb 2024 |
| Known as | RhACE2 | “APN01 is a soluble recombinant human angiotensin-converting enzyme 2 (rhACE2), a key player in the renin-aldosterone-angiotensin system (RAAS).” PMID 38375429 ↗ Feb 20241“RhACE2 APN01” NCT04335136 ↗ |
| Action | Restore | “repleting ACE2 using GSK2586881, a recombinant form of human angiotensin-converting enzyme 2 (rhACE2), could attenuate acute lung injury” PMID 28877748 ↗ Sep 2017 |
| Modality | Protein / enzyme biologic | “APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.” NCT00886353 ↗ |
| Route | Intravenous | “Recombinant human ACE2 (rhACE2) was administered intravenously to healthy human subjects” PMID 23681967 ↗ Sep 2013 |
| Target | AGT | “Angiotensinogen hydrolytic enzyme” CHEMBL4297887 ↗ |